Updated:
Zivo Bioscience, Inc.
Zivo Bioscience is a public biotech company developing microalgae-based therapies for immune modulation.
Zivo Bioscience, Inc.
Zivo Bioscience, Inc. is a biopharmaceutical company incorporated in Delaware and listed on the OTCQB under the ticker ZIVO. Its core technology derives from a microalgae strain it calls Algavive, which the firm says produces a bioactive compound capable of modulating innate immune responses. The company has not disclosed any family-office affiliation or wealth-management function; its operations are those of a publicly held drug developer, not an investment vehicle. Zivo's strategy centers on two primary therapeutic areas: human and animal health. The firm has run clinical trials for a potential treatment for bovine mastitis and is exploring applications in osteoarthritis and respiratory health. It has not publicly named specific portfolio companies or co-investors; its capital has been raised through public offerings and private placements. No data on team size, additional offices, or adjacent philanthropic vehicles is publicly available. The firm has no known deal flow from family offices or allocator networks. Zivo's structural differentiator is its microalgae-based platform, which is rare in biotech. The company operates as a public biotech, not as a capital allocator, and its governance follows corporate public-company standards.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Zivo Bioscience's relationship to family offices?
Zivo Bioscience is a publicly traded biotech company, not a family office. It has no disclosed affiliation with any single-family or multi-family office and does not manage third-party capital.
Does Zivo Bioscience make investments in other companies?
Zivo Bioscience does not function as an investment firm. Its activities are limited to internal drug development; it has not publicly reported any venture investments or direct holdings in other entities.
How is Zivo Bioscience funded?
The company has funded its operations through public equity offerings, private placements, and debt securities, per SEC filings. It does not manage or deploy capital for outside investors.
What is Zivo's core technology?
Zivo's platform is based on a proprietary microalgae strain, Algavive, which produces a compound that the firm claims can modulate innate immune responses. This has been studied in veterinary and human health contexts.
Is Zivo Bioscience a family office?
No. Zivo Bioscience is a biopharmaceutical company with no advisory or capital-allocation functions. It is classified here as a public biotech entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: